Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05326646
Other study ID # 2019/0332/HP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 19, 2023
Est. completion date August 2024

Study information

Verified date May 2023
Source University Hospital, Rouen
Contact Chloé Melchior, MD, PhD
Phone 0033232886707
Email chloe.melchior@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Treatments efficacy in irritable bowel syndrome (IBS) patients is inconstant and predictive factors of their efficacy are needed. The role of dysbiosis in IBS is well-known. Another way to identify microbiota differences is to assess its metabolic activity. It has been demonstrated that colonic pH in IBS patients is lower than in healthy volunteers, reflecting a highest colonic fermentation. Colonic acidification is able to sensitize colonic mechano-receptors to distension. Microbiota profile is able to predict the response to a low Fermentable Oligo, Di, Monosaccharides And Polyols (FODMAPs) diet, but is not available in clinical routine. The aim of our study is to assess the link between colonic fermentation (measured by colonic pH) and the efficacy of a low FODMAPs diet in IBS patients (measured by IBS severity scoring system (IBS-SSS)). We hypothesis that IBS patients with a lower colonic pH will have a better efficacy of the low FODMAPs diet. It might allow in the future personalized medicine. 50 IBS patients according to Rome IV criteria will be included in our study. All patients will have a measure of their colonic pH by wireless motility capsule. Patients will follow a low FODMAPs diet for 6 weeks after an education by a trained dietician. All participants will fill validated questionnaires before and after 6 weeks of low FODMAPs diet: IBS-SSS, Gastro Intestinal Quality of Life Index (GIQLI), Hospital Anxiety and Depression (HAD) scale. Microbiota, metabolomic and short chain fatty acid will be analysed before and after the intervention. The number of patients was calculated to assess the correlation between colonic pH and the variation of IBS-SSS before and after the intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - IBS according to Rome IV criteria - Normal blood test (cell blood count, C Reactive Protein, thyroid-stimulating hormone, anti transglutaminase antibodies) in the last 12 months - IBS severity score (IBS-SSS) >175/500 - IBS treatments stable in the last month - Effective contraception since 1 month for women in childbearing age Exclusion Criteria: - Anorexia nervosa or any eating disorders deemed incompatible - Organic gastroenterological diseases (inflammatory bowel disorder, microscopic colitis, gastrointestinal cancer, celiac disease) - Contra-indication to the wireless motility capsule (intestinal stenosis, digestive fistula or obstruction, history of bezoar, gastrointestinal surgery in the last 3 months, acute diverticulitis, cardiac pacemaker, implanted electromedical device, magnetic resonance imaging planned in the 5 days after the wireless motility capsule, swallowing disorder) - Breastfeeding or pregnant women - Participation in another clinical trial in the last 2 weeks - Patient who could not stop proton pump inhibitor treatment for 10 days - Person with administrative or judicial decision or under legal protection measure

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Low FODMAP diet
After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.

Locations

Country Name City State
France Rouen University Hospital Rouen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between efficacy of the low FODMAP diet on severity and the colonic pH Correlation between colonic pH (baseline) and the variation of IBS severity score (IBS-SSS). IBS-SSS is a score between 0 (no symptom) to 500 (highest symptom level). 6 weeks
Secondary Correlation between efficacy of the low FODMAP diet on quality of life and the colonic pH Correlation between colonic pH (baseline) and variation of the quality of life Index (GIQLI). GIQLI is a score between 0 (lowest quality of life) and 144 (best quality of life). 6 weeks
Secondary Correlation between efficacy of the low FODMAP diet on stool frequency and the colonic pH Correlation between colonic pH (baseline) and variation of the stool frequency 6 weeks
Secondary Correlation between efficacy of the low FODMAP diet on stool consistency and the colonic pH Correlation between colonic pH (baseline) and variation of the stool consistency (BSF) 6 weeks
Secondary Correlation between efficacy of the low FODMAP diet on anxiety and the colonic pH Correlation between colonic pH (baseline) and variation of anxiety (HAD). HAD anxiety is a scale comprised between 0 (no anxiety) and 21 (highest anxiety). 6 weeks
Secondary Correlation between efficacy of the low FODMAP diet on depression and the colonic pH Correlation between colonic pH (baseline) and variation of depression (HAD). HAD depression is a scale comprised between 0 (no depression) and 21 (highest depression). 6 weeks
Secondary Correlation between short chain fatty acids and the colonic pH Correlation between colonic pH (baseline) and variation of short chain fatty acids (in the stool) 6 weeks
Secondary Correlation between metabolites and the colonic pH Correlation between colonic pH (baseline) and variation of metabolites (in the stool). Among metabolites, short chain fatty acids, 28 biliary acids and lipopeptides (C12-GABA, C12-Glutamine, C14-Glutamine, C15-GABA, C16-Glutamate, C16-Glutamine, C18-GABA, C12:1-Alanine (Ala)-GABA, C12-Ala-GABA, C13-Ala-GABA, C14:1-Ala-GABA et C183OH-Glutamate-GABA) will be assessed. Metabolites will be also assessed by RMN spectroscopy that allow the assessment of a high ranges of different metabolites. 6 weeks
Secondary Colonic pH according to small intestinal bacterial overgrowth Comparison of colonic pH between patients with and without small intestinal bacterial overgrowth baseline
Secondary Colonic pH according to fructose malabsorption Comparison of colonic pH between patients with and without fructose malabsorption baseline
Secondary Colonic pH according to visceral hypersensitivity Comparison of colonic pH between patients with and without visceral hypersensitivity Baseline
Secondary Colonic pH and fecal calprotectin Correlation between colonic pH and fecal calprotectin Baseline
Secondary Colonic pH and rectal pain threshold Correlation between colonic pH and rectal pain threshold Baseline
Secondary Correlation between baseline QOL and the colonic pH Correlation between colonic pH and baseline GIQLI (quality of life Index) Baseline
Secondary Correlation between baseline IBS severity score and colonic pH Correlation between colonic pH and baseline IBS severity score (IBS-SSS) Baseline
Secondary Correlation between baseline anxiety and colonic pH Correlation between colonic pH and baseline anxiety (HAD) Baseline
Secondary Correlation between baseline depression and colonic pH Correlation between colonic pH and baseline depression (HAD) Baseline
Secondary Correlation between baseline stool consistency and colonic pH Correlation between baseline stool consistency (BSF) and colonic pH Baseline
Secondary Correlation between baseline stool frequency and colonic pH Correlation between baseline stool frequency and colonic pH Baseline
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A